New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case report
Key Clinical Message Sarcoidosis is a systemic inflammatory disease able to affect any organ within the body. Sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of rehabilitation. Early response to the treatments reinforces this hypothesis. The majority of sarcoidosis patients require immunosuppressive therapies, including corticosteroids. Abstract Most studies so far have focused on the management of COVID‐19 in patients suffering from sarcoidosis. Nevertheless, the current report aims to present a COVID‐19‐induced sarcoidosis case. Sarcoidosis is a systemic inflammatory disease with granulomas. Still, its etiology is unknown. It often affects the lungs and lymph nodes. A previously healthy 47‐year‐old female was referred with the following chief complaints: atypical chest pain, dry cough, and dyspnea on exertion within a month after COVID‐19 infection. Accordingly, a chest computed tomography revealed multiple conglomerated lymphadenopathies in the thoracic inlet, mediastinum, and hila. A core‐needle biopsy from the nodes revealed non‐necrotizing granulomatous inflammation, sarcoidal type. The sarcoidosis diagnosis was proposed and confirmed by a negative purified protein derivative (PPD) test. Accordingly, prednisolone was prescribed. All symptoms were relieved. A control lung HRCT was taken 6 months later, showing the lesions had disappeared. In conclusion, sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of disease convalescence..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Clinical Case Reports - 11(2023), 5 |
| Beteiligte Personen: |
Sadeghi, Somayeh [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 John Wiley & Sons Ltd. |
|---|
| Umfang: |
5 |
|---|
| doi: |
10.1002/ccr3.7339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015270327 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015270327 | ||
| 003 | DE-627 | ||
| 005 | 20231111134845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/ccr3.7339 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_CCR3_2023_11_5.zip.xml |
| 035 | |a (DE-627)WLY015270327 | ||
| 035 | |a (WILEY)CCR37339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Sadeghi, Somayeh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case report |
| 264 | 1 | |c 2023 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a Key Clinical Message Sarcoidosis is a systemic inflammatory disease able to affect any organ within the body. Sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of rehabilitation. Early response to the treatments reinforces this hypothesis. The majority of sarcoidosis patients require immunosuppressive therapies, including corticosteroids. Abstract Most studies so far have focused on the management of COVID‐19 in patients suffering from sarcoidosis. Nevertheless, the current report aims to present a COVID‐19‐induced sarcoidosis case. Sarcoidosis is a systemic inflammatory disease with granulomas. Still, its etiology is unknown. It often affects the lungs and lymph nodes. A previously healthy 47‐year‐old female was referred with the following chief complaints: atypical chest pain, dry cough, and dyspnea on exertion within a month after COVID‐19 infection. Accordingly, a chest computed tomography revealed multiple conglomerated lymphadenopathies in the thoracic inlet, mediastinum, and hila. A core‐needle biopsy from the nodes revealed non‐necrotizing granulomatous inflammation, sarcoidal type. The sarcoidosis diagnosis was proposed and confirmed by a negative purified protein derivative (PPD) test. Accordingly, prednisolone was prescribed. All symptoms were relieved. A control lung HRCT was taken 6 months later, showing the lesions had disappeared. In conclusion, sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of disease convalescence. | ||
| 700 | 1 | |a Mobarakeh, Shadi Reisizadeh |4 aut | |
| 700 | 1 | |a Momenzadeh, Mahnaz |4 aut | |
| 700 | 1 | |a Aria, Amir |4 aut | |
| 700 | 1 | |a Heidarpour, Mitra |4 aut | |
| 700 | 1 | |a Ahmadi, Somayeh Haji |4 aut | |
| 700 | 1 | |a Naderi, Zohreh |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical Case Reports |g 11(2023), 5 |w (DE-627)WLY003192814 |x 20500904 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:5 |g extent:5 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 5 |g 5 | ||